| MeSH term | MeSH ID | Detail |
|---|---|---|
| Fibrosis | D005355 | 23 associated lipids |
| Fistula | D005402 | 8 associated lipids |
| Foot Diseases | D005534 | 4 associated lipids |
| Fractures, Open | D005597 | 3 associated lipids |
| Fusobacterium Infections | D005674 | 3 associated lipids |
| Gastritis | D005756 | 27 associated lipids |
| Gastritis, Atrophic | D005757 | 4 associated lipids |
| Gastritis, Hypertrophic | D005758 | 1 associated lipids |
| Gastroesophageal Reflux | D005764 | 10 associated lipids |
| Gastrointestinal Diseases | D005767 | 20 associated lipids |
| Giardiasis | D005873 | 3 associated lipids |
| Glossitis, Benign Migratory | D005929 | 1 associated lipids |
| Granuloma, Plasma Cell | D006104 | 1 associated lipids |
| Hand Dermatoses | D006229 | 5 associated lipids |
| Hearing Disorders | D006311 | 10 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Heart Failure | D006333 | 36 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Hemophilia A | D006467 | 10 associated lipids |
| Gastrointestinal Hemorrhage | D006471 | 27 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gisbert JP et al. | Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? | 2005 | Am. J. Gastroenterol. | pmid:16128936 |
| Sontag SJ et al. | Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin. | 2001 | Am. J. Gastroenterol. | pmid:11374672 |
| Schaeverbeke T et al. | Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. | 2005 | Am. J. Gastroenterol. | pmid:16393213 |
| Chey WD and Wong BC | American College of Gastroenterology guideline on the management of Helicobacter pylori infection. | 2007 | Am. J. Gastroenterol. | pmid:17608775 |
| Savarino V et al. | What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? | 1995 | Am. J. Gastroenterol. | pmid:8540537 |
| Gisbert JP et al. | Response to article by Forné et al. | 1996 | Am. J. Gastroenterol. | pmid:8561132 |
| Cremonini F et al. | Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. | 2002 | Am. J. Gastroenterol. | pmid:12425542 |
| van Zanten SV and Thompson K | Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? | 2006 | Am. J. Gastroenterol. | pmid:16863548 |
| Rokkas T et al. | Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. | 2006 | Am. J. Gastroenterol. | pmid:16928256 |
| Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
| Coelho LG et al. | Once-daily Helicobacter pylori treatment to family members of gastric cancer patients. | 2000 | Am. J. Gastroenterol. | pmid:10710099 |
| Pilotto A et al. | In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. | 2000 | Am. J. Gastroenterol. | pmid:10710100 |
| Watson JB and Moss SF | Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. | 2011 | Am. J. Gastroenterol. | pmid:22056576 |
| van der Hulst RW et al. | Therapeutic options after failed Helicobacter pylori eradication therapy. | 1996 | Am. J. Gastroenterol. | pmid:8931413 |
| Alder JD et al. | Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies. | 1996 | Am. J. Gastroenterol. | pmid:8931416 |
| Zhou L et al. | A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. | 2014 | Am. J. Gastroenterol. | pmid:24642580 |
| Gisbert JP et al. | Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. | 2006 | Am. J. Gastroenterol. | pmid:16454825 |
| Stack WA et al. | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. | 1998 | Am. J. Gastroenterol. | pmid:9772054 |
| Adamek RJ and Bethke TD | Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. | 1998 | Am. J. Gastroenterol. | pmid:9772056 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Fennerty MB | Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. | 1998 | Am. J. Gastroenterol. | pmid:9448162 |
| Forné M et al. | Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. | 1998 | Am. J. Gastroenterol. | pmid:9448170 |
| Hsu PI et al. | A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. | 2005 | Am. J. Gastroenterol. | pmid:16279889 |
| Vakil N | Helicobacter pylori: factors affecting eradication and recurrence. | 2005 | Am. J. Gastroenterol. | pmid:16279890 |
| Sullivan B et al. | Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. | 2002 | Am. J. Gastroenterol. | pmid:12385435 |
| Chiba N | Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. | 1996 | Am. J. Gastroenterol. | pmid:8855737 |
| Gisbert JP et al. | Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. | 2008 | Am. J. Gastroenterol. | pmid:17764498 |
| Odaka T et al. | Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. | 2002 | Am. J. Gastroenterol. | pmid:11922552 |
| Giannini E et al. | Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. | 2000 | Am. J. Gastroenterol. | pmid:11051345 |
| Vakil N and Cutler A | Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10235192 |
| Scholte GH et al. | Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy. | 2002 | Am. J. Gastroenterol. | pmid:12135019 |
| Savarino V et al. | New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. | 1995 | Am. J. Gastroenterol. | pmid:7717343 |
| Kawasaki M et al. | Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. | 1997 | Am. J. Gastroenterol. | pmid:9382064 |
| Adamek RJ et al. | Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. | 1997 | Am. J. Gastroenterol. | pmid:9382084 |
| Murata H et al. | Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. | 1998 | Am. J. Gastroenterol. | pmid:9820380 |
| Laine L et al. | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. | 1998 | Am. J. Gastroenterol. | pmid:9820381 |
| Hasegawa T et al. | Image of the month: Disseminated Nontuberculous Mycobacteriosis. | 2015 | Am. J. Gastroenterol. | pmid:26673493 |
| de Boer WA et al. | Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. | 1998 | Am. J. Gastroenterol. | pmid:9672338 |
| Vakil N and Fennerty MB | Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. | 1996 | Am. J. Gastroenterol. | pmid:8607487 |
| Treiber G | The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. | 1996 | Am. J. Gastroenterol. | pmid:8607488 |
| Shaheen N and Grimm IS | Fulminant hepatic failure associated with clarithromycin. | 1996 | Am. J. Gastroenterol. | pmid:8607519 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. | 1998 | Am. J. Gastroenterol. | pmid:9517644 |
| Adamek RJ et al. | Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. | 1998 | Am. J. Gastroenterol. | pmid:9517645 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| van der Wouden EJ et al. | One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. | 1998 | Am. J. Gastroenterol. | pmid:9707042 |
| Parasakthi N and Goh KL | Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. | 1995 | Am. J. Gastroenterol. | pmid:7872306 |
| Laine L et al. | Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. | 1997 | Am. J. Gastroenterol. | pmid:9399755 |
| Srinivasan R and Minocha A | Cure of Helicobacter pylori: a hidden curse? | 1997 | Am. J. Gastroenterol. | pmid:9399784 |
| Veldhuyzen van Zanten S et al. | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. | 2003 | Am. J. Gastroenterol. | pmid:14499772 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |